CAD may lead to an 8 percent increase in adenoma detection rate and 2 percent increase in detection rate of advanced colorectal neoplasia.

An analysis of 2 pharmacovigilance databases revealed a high prevalence of azacitidine-related adverse events in patients with MDS or AML.

Cancer patients may have an increased risk of developing second primary malignancies after immune checkpoint inhibitor therapy.

Study results suggest that “telemedicine represents a unique opportunity to reduce time and travel burdens for patients with cancer considering clinical trials,” according to researchers.

Results from a meta-analysis suggest patients with resectable dMMR/MSI-H gastric cancer can forgo perioperative chemotherapy.

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” ...

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

After 3.5 years of follow-up, there was a 98% rate of minimal residual disease, and 9 patients were still in complete remission.

Cabozantinib significantly improved progression free survival in patients with pNET and epNET compared with placebo.